MLTX

MoonLake is a pre-revenue, single-asset clinical-stage biotech whose entire value rests on sonelokimab (SLK), an IL-17A/F Nanobody licensed from Merck KGaA. There is no product revenue in any year shown (FY2021–FY2025), and losses are accelerating: net income fell to -$227M in FY2025 from -$119M in FY2024, operating loss widened 71.1% to -$245M, and diluted EPS was -$3.53. ROE is -74.7% against an accumulated deficit of -$463M. This is not a company you value on fundamentals — it is a probability-weighted bet on a regulatory outcome, which the methodology treats as unknowable risk.

The pivotal data is genuinely mixed, and that is the crux. In September 2025 the Phase 3 VELA program in hidradenitis suppurativa delivered a split result: VELA-1 hit statistical significance on all primary and key secondary endpoints (HiSCR75 delta to placebo 17%, p<0.001), but VELA-2 missed its week-16 primary endpoint on the composite strategy (delta to placebo 9%, p=0.053) because of a higher-than-expected placebo arm — even though SLK's own 34% HiSCR75 response was nearly identical across both trials. A missed pivotal endpoint, regardless of the placebo explanation, introduces real regulatory and approvability uncertainty for the lead (and only) asset, which is why the stock sits at $19.91, well off its prior range.